Evidence map›Paper›PMID 31659099›Full record

Trial reportCancer genomics & proteomics

Cell Cycle Regulator p27 Mediates Body Mass Index Effects in Ovarian Cancer in FIGO-stages I-II.

Ingiridur Skirnisdottir, Helena Akerud, Tomas Seidal, Inger Sundstrom-Poromaa

Open access · diamondAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ingiridur SkirnisdottirDepartment of Women's and Children's Health, Uppsala University, Uppsala, Sweden ingiridur.skirnisdottir@kbh.uu.se.
Helena AkerudDepartment of Immunology, Genetics and Pathology Uppsala University, Uppsala, Sweden.
Tomas SeidalDepartment of Pathology, Halmstad Medical Center Hospital, Halmstad, Sweden.
Inger Sundstrom-PoromaaDepartment of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Uppsala University · SEHalmstad University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe aim of the present study was to evaluate the association between body mass index (BMI), the biomarker p27, and the clinical factors in FIGO-stages I-II ovarian cancer. PATIENTS AND

methodsA total of 128 patients with ovarian cancer were included in the study. For testing differences in univariate analyzes we used the Pearson's Chi-square test and the log-rank test. For multivariate analyses the logistic regression and Cox regression models were used with recurrent disease and disease-free survival as endpoints, respectively.

resultsPatients with BMI ≤25 kg/m

conclusionThe cell cycle regulator p27 mediates BMI effects in ovarian cancer in FIGO-stages I-II.

Indexed as

Body Mass IndexAdultCyclin-Dependent Kinase Inhibitor p27Disease-Free SurvivalFemaleHumansMiddle AgedNeoplasm StagingOvarian NeoplasmsSurvival RateCDKN1B protein, humanCyclin-Dependent Kinase Inhibitor p27BMIFIGO-stages I-IInon-serous tumorsovarian cancerp27

Identifiers

PMID31659099
PMCPMC6885371
OpenAlexW2982668471

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.